Eurazeo has Announced the Sale of its Stake in Neovia

Eurazeo, Idia, Future French Champions, and Unigrains, Neovia shareholders since 2015 alongside InVivo (historical majority shareholder), have announced the effective sale of all Neovia shares to Archer Daniels Midland Company (NYSE: ADM). Over the past three years, spurred by Eurazeo and InVivo, its historical shareholder, as well as its management team, Neovia has undergone an in-depth transformation and accelerated its international reach, while expanding into high added-value businesses. Over the period, the company carried out more than 15 acquisitions worldwide, boosting its revenue outside Europe from 52% to nearly 75%. Backed by its new shareholder, with its highly complementary market positions, Neovia is well positioned to further its global leadership in animal nutrition. Transaction sales proceeds for Eurazeo and its investor partners total €225 million, including €170 million for Eurazeo, representing a return on its initial investment of nearly 2x and an IRR of approximately 20%.


About Eurazeo:

Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable private equity, venture capital, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. Eurazeo has offices in Paris, New York, Sao Paulo, Buenos Aires, Shanghai, London, Luxembourg, Frankfurt and Madrid.


Source: Eurazeo press release

Email this to someoneShare on LinkedInShare on FacebookTweet about this on TwitterShare on Google+